Estrogens, Conjugated
Brand names: Premarin
At a glance
- Medicare prescriptions, 2024
- 258,807
- Medicare drug cost
- $97.7M
- Average cost per prescription
- $378
- Clinicians who prescribed it
- 13,653
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
PREMARIN is a mixture of estrogens indicated for: • Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause • Treatment of Moderate to Severe Vulvar and Vaginal Atrophy due to Menopause • Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure • Treatment of Breast Cancer (for Palliation Only) in Appropriately Selected Women and Men with Metastatic Disease • Treatment of Advanced Androgen-Dependent Carcinoma of the Prostate (for Palliation Only) • Prevention of Postmenopausal Osteoporosis 1.1 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause 1.2 Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause Limitations of Use When prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, topical vaginal products should be considered. 1.3 Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure 1.4 Treatment of Breast Cancer (for Palliation Only) in Appropriately Selected Women and Men with Metastatic Disease 1.5 Treatment of Advanced Androgen-Dependent Carcinoma of the Prostate (for Palliation Only) 1.6 Prevention of Postmenopausal Osteoporosis Limitations of Use When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of…
From the FDA-approved prescribing information (label dated June 2026). Full labels on DailyMed (opens in a new tab)
Boxed warning
WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, BREAST CANCER and PROBABLE DEMENTIA
The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.
Who prescribes it
- OB-GYN (Obstetrics & Gynecology) 32.6%
- Family Medicine 19.7%
- Internal Medicine 17.0%
- Nurse Practitioners 13.5%
- Physician Assistants 4.7%
- Urology 4.2%
- Urogynecology 4.0%
- General Practice 0.9%
- Geriatric Medicine 0.8%
- Certified Nurse-Midwives 0.3%
- Endocrinology & Diabetes 0.3%
- Gynecologic Oncology 0.2%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions fell 31% from 2019 to 2024.
Biggest change by state since 2019
- Puerto Rico +14%
- Iowa −14%
- Louisiana −19%
- Oklahoma −20%
- Missouri −22%
- California (smallest change) −40%
- Illinois (smallest change) −38%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 3 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Ingenus Pharmaceuticals, LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 0.3 mg | green oval tablet, 12 mm | CT1 NL |
| 0.45 mg | blue oval tablet, 12 mm | CT2 NL |
| 0.625 mg | brown oval tablet, 12 mm | CT3 NL |
U.S. Pharmaceuticals
| Strength | Looks like | Imprint |
|---|---|---|
| 0.45 mg / 20 mg bazedoxifene acetate | pink oval tablet, 12 mm | 045 20 |
Wyeth Pharmaceuticals LLC, A Subsidiary of Pfizer Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 0.3 mg | green oval tablet, 10 mm | PREMARIN 03 |
| 0.45 mg | blue oval tablet, 10 mm | PREMARIN 045 |
| 0.625 mg | brown oval tablet, 10 mm | PREMARIN 0625 |
| 0.9 mg | white oval tablet, 12 mm | PREMARIN 09 |
| 1.25 mg | yellow oval tablet, 14 mm | PREMARIN 125 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $7,400 in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Pfizer Inc. $5,400
- Wyeth Pharmaceuticals LLC $2,000
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.